William B. Walkup & Associates Inc. Invests $31,000 in Organon & Co. (NYSE:OGN)

William B. Walkup & Associates Inc. bought a new position in shares of Organon & Co. (NYSE:OGN) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 1,514 shares of the company’s stock, valued at approximately $31,000.

Other large investors also recently modified their holdings of the company. Susquehanna Fundamental Investments LLC acquired a new position in shares of Organon & Co. during the first quarter worth approximately $6,284,000. Friedenthal Financial acquired a new position in shares of Organon & Co. during the second quarter worth approximately $769,000. Vanguard Group Inc. lifted its holdings in Organon & Co. by 0.6% in the first quarter. Vanguard Group Inc. now owns 30,789,850 shares of the company’s stock valued at $578,849,000 after buying an additional 192,613 shares during the period. Janney Montgomery Scott LLC lifted its holdings in Organon & Co. by 23.9% in the first quarter. Janney Montgomery Scott LLC now owns 263,051 shares of the company’s stock valued at $4,945,000 after buying an additional 50,788 shares during the period. Finally, Los Angeles Capital Management LLC acquired a new position in Organon & Co. in the first quarter valued at approximately $3,184,000. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. JPMorgan Chase & Co. lowered shares of Organon & Co. from a “neutral” rating to an “underweight” rating and increased their price objective for the company from $18.00 to $20.00 in a report on Friday, September 6th. Evercore ISI upgraded shares of Organon & Co. to a “strong-buy” rating in a report on Wednesday, September 18th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $21.00.

Organon & Co. Trading Down 0.3 %

Shares of NYSE OGN opened at $19.12 on Tuesday. The company’s fifty day moving average is $20.79 and its 200-day moving average is $20.16. The stock has a market cap of $4.92 billion, a price-to-earnings ratio of 4.67, a P/E/G ratio of 0.87 and a beta of 0.85. Organon & Co. has a twelve month low of $10.84 and a twelve month high of $23.10. The company has a quick ratio of 1.17, a current ratio of 1.64 and a debt-to-equity ratio of 60.05.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $1.08 by $0.04. The company had revenue of $1.61 billion for the quarter, compared to analysts’ expectations of $1.61 billion. Organon & Co. had a net margin of 15.76% and a negative return on equity of 840.29%. The business’s quarterly revenue was down .1% compared to the same quarter last year. During the same period last year, the firm posted $1.31 earnings per share. Equities research analysts predict that Organon & Co. will post 4.14 EPS for the current year.

Organon & Co. Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, September 12th. Stockholders of record on Friday, August 16th were given a dividend of $0.28 per share. The ex-dividend date was Friday, August 16th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 5.86%. Organon & Co.’s dividend payout ratio is 27.38%.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.